Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13405624 | 0.83 | BACE1 (0.31) | BACE1 | |
| SCHEMBL3803489 | 0.83 | BACE1 (0.40) | BACE1 | |
| SCHEMBL2595636 | 0.77 | HSD11B1 (0.34) | HSD11B1CXCR2 | |
| SCHEMBL31387213 | 0.77 | BACE1 (0.33) | BACE1 | |
| SCHEMBL1448551 | 0.77 | — | — | |
| SCHEMBL1128010 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL19570441 | 0.76 | BACE1 (0.33) | BACE1HSD11B1 | |
| SCHEMBL15181869 | 0.76 | BACE1 (0.39) | BACE1 | |
| SCHEMBL14537415 | 0.75 | CXCR2 (0.33) | BACE1HSD11B1CXCR2 | |
| SCHEMBL4852116 | 0.75 | BACE1 (0.40) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11672782-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3143018-B1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| US-20210052554-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| US-20200268718-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| CN-106661012-B | Carboxamide derivatives | 诺华股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-10195181-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | disclosed |
| EP-3143018-A1 | CARBOXAMIDE DERIVATIVES | Novartis AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| US-20170014388-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9403810-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
| WO-2015175796-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052554-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | BACE1 1961/4885HSD11B1 1291/4885CXCR2 1812/4885 |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | SIRT1, ADCY5, ASIC1 | BACE1 1677/4885HSD11B1 1000/4885CXCR2 1697/4885 |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | BACE1 3750/4885HSD11B1 1583/4885CXCR2 1945/4885 |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | BACE1 1961/4885HSD11B1 1291/4885CXCR2 1812/4885 |
| US-11672782-B2 | Carboxamide derivatives | SIRT5, SIRT7, ADCY5 | BACE1 1961/4885HSD11B1 1291/4885CXCR2 1812/4885 |
| US-20200268718-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | BACE1 1961/4885HSD11B1 1291/4885CXCR2 1812/4885 |
| US-20170014388-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | BACE1 1961/4885HSD11B1 1291/4885CXCR2 1812/4885 |
| US-10195181-B2 | Carboxamide derivatives | SIRT5, SIRT7, ADCY5 | BACE1 1961/4885HSD11B1 1291/4885CXCR2 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.